Antibodies for the treatment of diffuse large cell lymphoma

Seminars in Oncology

Volumn 30, Issue 4, 2003, Pages 448-456

  Blum, Kristie A ^b   Bartlett, Nancy L ^a  

^a MO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; METHYLPREDNISOLONE SODIUM SUCCINATE; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISOLONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

AUTOTRANSPLANTATION; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; DRUG POTENTIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LARGE CELL LYMPHOMA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0042737459     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00251-3     Document Type: Article

References (61)

1. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
2. Shipp MA, Harrington DP, Anderson JR, et al: The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
3. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four dose treatment regimen. J Clin Oncol 16:2825-2833, 1998
4. Hainsworth JD, Burris HA III, Morrissey LH, et al: Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95: 3052-3056, 2000
5. Hainsworth JD, Litchy S, Burris HA III, et al: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20:4261-4267, 2002
6. Czuczman MS, Grillo-Lopez AJ, White CA, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999
7. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998
8. Demiden A, Lam T, Alas S, et al: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B-cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12:177-186, 1997
9. Chow KU, Solnmerlad WD, Boeher S, et al: Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases. Haematologica 87:33-43, 2002
10. Gaetano ND, Xiao Y, Erba E, et al: Synergism between fludarabine and rituximab revealed in follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Hematol 114:800-809, 2001
11. Rose AL, Smith BE, Maloney DG: Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 100:1765-1773, 2002
12. Miller TP, Dahlberg S, Cassady JR, et al: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339:21-26, 1998
13. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
14. Vose JM, Link BK, Grossbard ML, et al: Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19:389-397, 2001
15. Vose JM, Link BK, Grossbard ML, et al: Long term follow-up of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma (NHL). Blood 100:1396, 2002 (suppl 1, abstr)
16. Wilson WH, Pittaluga S, O'Connor P, et al: Rituximab may overcome bcl-2 associated chemotherapy resistance in untreated large B-cell lymphomas. Blood 98:1447, 2001 (suppl 1, abstr)
17. Wilson WH, Gutierrez M, O'Connor P, et al: The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R. Semin Oncol 29:41-47, 2002
18. Wilson WH, Grossbard ML, Alvarez M, et al: Dose-escalating EPOCH chemotherapy (CT) in previously untreated large cell lymphoma (LCL). Proc Am Soc Clin Oncol 17:17a, 1998 (abstr)
19. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346:235-242, 2002
20. Gascoyne RD, Adomat SA, Krajewski S, et al: Prognostic significance of bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90:244-251, 1997
21. Hermine O, Haioun C, Lepage E, et al: Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 87:265-272, 1996
22. Mounier N, Briere J, Gisselbrecht C, et al: Rituximab plus CHOP (R-CHOP) in the treatment of elderly patients with diffuse large B-cell lymphoma (DLBCL) overcomes bcl2-associated chemotherapy resistance. Blood 100:603, 2002 (suppl 1, abstr)
23. Kewalramani T, Zelenetz A, Bertino J, et al: Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy. Blood 98:1459, 2001 (suppl 1, abstr)
24. Younes A, McLaughlin P, Hagemeister FB, et al: High respons rate and complete remission rate achieved by adding rituximab to Taxol plus topotecan (TTR) with G-CSF support for the treatment of patients with relapsed/refractory aggressive B-cell lymphomas. Blood 98:1456, 2001 (suppl 1, abstr)
25. Kramer A, Zoz M, Krasniqi F, et al: Treatment of patient with relapsed or refractory aggressive non-Hodgkin's lymphoma with a combination of taxane, cyclophosphamide, and rituximab. Blood 98:569, 2001 (suppl 1, abstr)
26. Weng W, Levy R: Analysis of IgG Fc receptor FcR111a polymorphism in relapsed follicular non-Hodgkin's lymphoma patients treated with rituximab. Blood 100:1368, 2002 (suppl 1, abstr)
27. Kennedy GA, Tey S, Cobcroft R, et al: Incidence and nature of CD20 negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: A retrospective review. Blood 100:1394, 2002 (suppl 1, abstr)
28. Flinn IW, Jones RJ, Goodrich A, et al: Rituximab during autologous stem cell transplantation for lymphoma produces lymphoma free grafts in most patients by PCR and clonogenic assays. Blood: 98:2832, 2001 suppl 1, abstr)
29. Tarella C, Ladetto M, Magni M, et al: Rituximab-supplemented high dose chemotherapy with autografting in high-risk B-diffuse large cell lymphoma: A multicenter, prospective study of GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Blood 100:2546, 2002 (suppl 1, abstr)
30. Horwitz SM, Negrin RS, Stockerl-Goldstein KE, et al: Phase II trial of rituximab as adjuvant therapy to high dose chemotherapy and peripheral blood stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphomas. Blood 98:3578, 2001 (suppl 1, abstr)
31. Benelki M, Shafi F, Qureshi A, et al: The effect of rituximab on peripheral blood stem cell mobilization in non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 21:1666, 2002 (abstr)
32. + cell yield in patients mobilized with etoposide plus G-CSF. Blood 98:3075, 2001 (suppl 1, abstr)
33. Ehmann WC, Mierski JA, Claxton DF, et al: Unexpected toxicities of combined rituximab and GM-CSF in autologous transplants for CD20 positive lymphoma. Blood 98: 5150, 2001 (suppl 1, abstr)
34. Senderowicz AM, Vitetta E, Headlee D, et al: Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin. Ann Intern Med 126:882-885, 1997
35. Benketrou M, Jais J, Leblond V, et al: Anti-B-cell monoclonal antibody treatment of severe post-transplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome. Blood 92:3137-3147, 1998
36. Horwitz SM, Tsai D, Twist C, et al: Rituximab is effective therapy for post-transplant lymphoproliferative disorder (PTLD) not responding to reduction in immunosuppression a prospective trial in adults and children. Proc Am Soc Clin Oncol 21:1134, 2001 (abstr)
37. Morrison VA, Bartlett N, Dunn D, et al: Rituximab therapy for post-transplant lymphoproliferative disorders (PTLD): Preliminary outcome results. Proc Am Soc Clin Oncol 21:1177, 2001 (abstr)
38. Oertel SHK, Zeidler K, Grefer J, et al: Monotherapy with the anti-CD20 antibody rituximab in patients with post-transplant lymphoproliferative disease (PTLD): Results of a multicenter phase II study. Blood 100:2250, 2002 (suppl 1, abstr)
39. Kentos A, Knoop C, Wissing M, et al: Anti-CD20 monoclonal antibody as first-line treatment of post-transplant B-lymphoproliferative disorders in solid organ transplant recipients. A report of 8 cases observed in a single center. Blood 100:1451, 2002 (suppl 1, abstr)
40. Miliped N, Vasseur B, Parquet N, et al: Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis in 32 patients. Ann Oncol 11:S113-S116, 2000 (suppl 1)
41. Weiss R, Golkel L, Arasteh K, et al: HIV-related lymphoma: Rituximab concomitant to second-line chemotherapy following tumor progression under CHOP or early relapse. Blood 98:4744, 2001 (suppl 1, abstr)
42. Straus DJ, Huang J, Testa MA, et al: Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: Analysis of AIDS Clinical Trials Group protocol 142-Low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. J Clin Oncol 16:3601-3606, 1998
43. Tirelli U, Sparano J, Hopkins U, et al: Pilot trial of infusion cyclophosphamide, doxorubicin, and etoposide plus the anti-CD20 monoclonal antibody rituximab in HIV-associated non-Hodgkin's lymphomas. Proc Am Soc Clin Oncol 19:170, 2000 (abstr)
44. Ruhstaller TW, Amster U, Cerny T: Rituximab: Active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann Oncol 11:374-375, 2000
45. Schulz H, Pels H, Hom E, et al: Intraventricular treatment of relapsed and refractory central nervous system lymphoma with rituximab. Blood 98:4725, 2001 (suppl 1, abstr)
46. Rubenstein JL, Combs D, Rosenberg J, et al: Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 101:466-468, 2003
47. Abrey LE, Yahalom J, DeAngelis LM: Treatment for primary CNS lymphoma: The next step. J Clin Oncol 18:3144-3150, 2000
48. Davis TA, Maloney DG, Grillo-Lopez AJ, et al: Combination immunotherapy of relapsed of refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res 6:2644-2652, 2000
49. Hurst D, Gluck L, Yuen A, et al: IL-2 plus rituximab results in clinical responses in advanced patients with non-Hodgkin's lymphoma related to the degree of NK expansion. Ann Oncol 13:290, 2002 (suppl 1, abstr)
50. Ansell SM, Witzig TE, Kurtin PJ, et al: Phase I study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 99:67-74, 2002
51. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed, refractory low-grade, follicular or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20: 2453-2463, 2002
52. + B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793-3803, 1999
53. Bartlett NL, Witzig TE, Gordon LI, et al: Y90-ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B-cell non-Hodgkin's lymphoma (NHL) patients. Proc Am Soc of Clin Oncol 21:51, 2002 (abstr)
54. Vose JM, Wahl RL, Saleh M, et al: Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/ refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 18:1316-1323, 2000
55. Kaminski MS, Zelenetz AD, Press OW, et al: Pivotal study of iodine 1 131 tositumomab for chemotherapy-refractory low-grade of transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19:3918-3928, 2001
56. Leonard JP, Coleman M, Matthew JC, et al: Phase I/II trial of Epratuzumab (humanized anti-CD22 antibody) in non-Hodgkin's lymphoma. Blood 100:1388, 2002 (suppl 1, abstr)
57. Link BK, Wang H, Byrd JC, et al: Phase I study of HulD10 monoclonal antibody in patients with B-cell lymphoma. Proc Am Soc Clin Oncol 20:1135, 2001 (abstr)
58. Hegde U, White T, Stetler-Stevenson M, et al: Phase 1 study of combination rituximab (CD20) and apolizumab (Hu1D10) monoclonal antibody therapy in previously treated B-cell lymphoma and chronic lymphocytic leukemia. Blood 100:1389, 2002 (suppl 1, abstr)
59. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 16:3246-2356, 1998
60. Czuczman MS, Witzig TE, Younes A, et al: IDEC-114, anti-CD80 monoclonal antibody for relapsed or refractory, follicular NHL: Phase I/II study of safety, efficacy, and pharmacokinetics. Blood 100:610, 2002 (suppl 1, abstr)
61. Lundin J, Osterborg A, Brittinger G, et al: Campath-1H monoclonal antibody in therapy for previously treated lowgrade non-Hodgkin's lymphomas: A phase II multicenter study. European study group of Campath-1H treatment in low-grade non-Hodgkin's lymphoma. J Clin Oncol 16:3257-3263, 1998